Three Momentum Stocks, but Only One Looks Clean Enough to Buy

This group has plenty of movement, but the quality is not equal. One stock is being chased despite a major earnings miss, one is getting repriced around a more credible AI infrastructure story, and one is still a solid solar infrastructure name with a less impressive 2027 profit outlook. The setup is simple: avoid the weakest fundamentals, buy the cleaner AI trend, and hold the mixed solar story.

A small biotech just passed 75% enrollment in a late-stage clinical trial at some of the top heart centers in the U.S. - Cleveland Clinic, Mayo Clinic, Mass General, and Columbia.

The company's drug already showed clear, measurable results in a mid-stage trial published in a leading medical journal. Now it's going after a recurring heart condition where the only approved treatment is a weekly injection expected to do nearly $950 million in sales this year - and 82% of patients still aren't being treated.

Wall Street already has two Buy ratings on the stock with price targets 3-4x the current share price.

Get the full report

*This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

Futures are broadly higher as traders wait for another inflation check with April PPI on deck. Tech is trying to steady after Tuesday’s pullback, while higher oil and renewed U.S.-Iran tension keep the rally from feeling completely clean.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• Alibaba Group Holding Limited [BABA]
• Takeda Pharmaceutical Company Limited [TAK]
• Nebius Group N.V. [NBIS]
• Tower Semiconductor Ltd. [TSEM]
• Dynatrace, Inc. [DT]

Earnings (Aftermarket):
• Cisco Systems, Inc. [CSCO]
• Manulife Financial Corp [MFC]

Economic Reports:
• Producer price index (April): 8:30 am
• Core PPI (April): 8:30 am
• PPI year over year: 8:30 am
• Core PPI year over year: 8:30 am

Six insiders at a manufacturing and infrastructure stock sold roughly $27.2 million after shares jumped more than 78% in a month, while a senior executive at a data storage giant sold another $5.0 million after an almost 900% one-year run.

Our free members just hear about insiders taking profits. Insider readers will see where leadership is reducing exposure after the market already paid up.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Wolfspeed Inc (NYSE: WOLF) is trading like a comeback story with rocket fuel behind it. The stock has surged more than 1,200% over the past year, pushed to a fresh 52-week high, and added another 43% premarket as investors continue to chase the silicon carbide recovery trade.

The problem is that the latest operating numbers do not justify that kind of confidence yet. Wolfspeed’s recent quarter missed badly, with EPS of -$3.26 versus expectations for -$0.56, while revenue came in at $150.2 million against the $209.76 million consensus.

That is not a small miss. That is a reminder that the company is still dealing with serious execution and restructuring challenges.

The stock’s low stated P/E looks tempting on the surface, but this is not a normal value setup. Wolfspeed is moving on balance sheet hopes, restructuring optimism, and renewed enthusiasm for semiconductor names tied to power, EVs, and industrial demand. Those can keep a stock moving, but they do not erase the need for cleaner revenue and earnings delivery.

My Take For You: Wolfspeed has momentum, but the business has not earned this much enthusiasm yet. This is a trader’s stock right now, not a clean operating recovery.

My Verdict: Avoid chasing this. The risk is that the stock’s massive run reverses fast when investors refocus on missed numbers and restructuring risk.

Penguin Solutions Inc (NASDAQ: PENG) is getting a fresh bid as investors refocus on its raised fiscal 2026 outlook and AI infrastructure positioning. The company has been highlighting its OriginAI factory and inference platform, along with partnerships that make it look more relevant as AI workloads move beyond training and into broader deployment.

That matters because inference is where the next phase of AI infrastructure spending gets more practical. Companies do not just need giant model-training clusters.

They need systems that can run AI workloads reliably, repeatedly, and closer to the point of use. Penguin’s positioning gives the market a reason to view it as more than a generic hardware infrastructure name.

The stock is already up more than 127% over the past year and trades around 61.7x earnings, so this is not a cheap setup. But the stock’s 17% premarket move shows investors are willing to pay up for companies with direct AI infrastructure exposure and a raised outlook.

The key is whether management can turn the AI narrative into sustained sales growth rather than one momentum burst.

My Take For You: Penguin is becoming a more credible AI infrastructure story because the focus is shifting toward inference, where demand should keep broadening. The stock is expensive, but the theme is real.

My Verdict: Buy this. The risk is that AI-infrastructure enthusiasm outruns actual order growth and compresses the multiple.flashy, but quietly earning its keep.

In acute care, the difference between minutes and hours can decide outcomes.

One small biotech is showing absorption and platelet effects in minutes through its sublingual delivery tech, well ahead of what traditional pills can do.

Its first aspirin trials are already turning heads.

Here's why it's getting attention.

Nextpower Inc (NASDAQ: NXT) delivered a strong first-quarter beat, but the forward guide makes the stock a little more complicated. Revenue came in at $880.5 million, ahead of the $827 million estimate, while adjusted EPS of $1.05 beat the $0.93 consensus. Adjusted EBITDA reached $201.8 million, also ahead of expectations, with a 22.9% adjusted EBITDA margin.

The company still has a strong long-term profile. Revenue has grown at a 24.4% annualized rate over the past five years, and the stock is up more than 130% over the past year as investors continue to reward solar tracker demand and infrastructure exposure.

Free cash flow also came in at $153.6 million, equal to a 17.4% margin, which is still strong even though it was down from last year.

The issue is guidance. Full-year revenue guidance of $3.95 billion came in slightly above estimates, but 2027 adjusted EPS guidance of $4.40 missed analyst expectations by 8.2%, and 2027 EBITDA guidance also landed below consensus. That does not break the story, but it does make the premarket jump harder to chase.

My Take For You: Nextpower remains a high-quality solar infrastructure name, but the mixed guide argues for discipline. The quarter was strong, but the forward earnings setup is not clean enough to treat this as a no-brainer breakout.

My Verdict: Hold this. The risk is that investors punish the stock once the focus shifts from the Q1 beat to softer 2027 profit guidance.

QuantumScape is moving higher as investors focus on the Eagle Line pilot ramp and the company’s first $11 million in customer billings. That is not GAAP revenue, but it is still an important step because it shows partners are starting to pay around the solid-state battery ecosystem.

The problem is scale. QuantumScape still lost $100.8 million in Q1 and expects a full-year adjusted EBITDA loss of $250 million to $275 million. The technology is promising, but the business is still in proof mode.

Rocket Lab is climbing as traders pile into space-defense names tied to the Golden Dome missile-defense push. The big number is massive: the CBO estimates the program could cost $1.2 trillion over 20 years, with a huge portion tied to space-based systems.

Rocket Lab has a real angle here. It was selected with Raytheon for the U.S. Space Force’s Space-Based Interceptor program, and it already has a $2.2 billion backlog plus record quarterly revenue of $200.3 million.

Karman is selling off because the quarter was strong but not strong enough. Revenue hit a record $151.2 million, up 51% year over year, but it still missed estimates. Adjusted EPS of $0.11 also came in light, and full-year revenue guidance of $720 million to $735 million sits below the Street’s roughly $740 million expectation.

The backlog is the bright spot at $1 billion, up 61% from last year. But after a big defense-stock run, investors wanted a clean beat and a stronger guide.

One drug company is making nearly $1 billion a year treating a recurring heart condition with a weekly injection - and 82% of eligible patients still aren't on therapy.

Now a small biotech is developing an oral alternative. Its mid-stage trial already showed real, measurable results published in a top medical journal. And its late-stage trial is 75%+ enrolled at Cleveland Clinic, Mayo Clinic, and Mass General.

The market is proven. The unmet need is massive. And late-stage data could be months away.

Read the full breakdown here

*This communication is a paid advertisement and is not editorial content, independent research, or an unbiased analysis. Read this disclosure in full before reading the article it accompanies.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.